Clinical trial with barbexaclone on epilepsies

Abstract

An open clinical trial with barbexaclone, which is an association of phenobarbital with light stimulation of the central nervous system (iota 1 cyclohexyl 2 methylaminopropane), for the treatment of epileptic disorders is reported. The authors studied 40 patients between 0-12 yr of age, of both sexes, all of them having convulsive seizures of the grand mal type, associated or not with other epileptic manifestations. After analyzing the different aspects of the group they consider their results satisfactory: very good or good in 82.5% of the cases.